SG11202006409TA - Biaryl derivative, preparation method therefor and pharmaceutical use thereof - Google Patents
Biaryl derivative, preparation method therefor and pharmaceutical use thereofInfo
- Publication number
- SG11202006409TA SG11202006409TA SG11202006409TA SG11202006409TA SG11202006409TA SG 11202006409T A SG11202006409T A SG 11202006409TA SG 11202006409T A SG11202006409T A SG 11202006409TA SG 11202006409T A SG11202006409T A SG 11202006409TA SG 11202006409T A SG11202006409T A SG 11202006409TA
- Authority
- SG
- Singapore
- Prior art keywords
- preparation
- method therefor
- pharmaceutical use
- biaryl derivative
- biaryl
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D213/81—Amides; Imides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/10—Spiro-condensed systems
- C07D491/107—Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201810111413 | 2018-02-05 | ||
| CN201810770644 | 2018-07-13 | ||
| PCT/CN2019/073594 WO2019149183A1 (en) | 2018-02-05 | 2019-01-29 | Biaryl derivative, preparation method thereof and pharmaceutical application thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11202006409TA true SG11202006409TA (en) | 2020-08-28 |
Family
ID=67479570
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11202006409TA SG11202006409TA (en) | 2018-02-05 | 2019-01-29 | Biaryl derivative, preparation method therefor and pharmaceutical use thereof |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US11459339B2 (en) |
| EP (1) | EP3750887A4 (en) |
| JP (1) | JP7033343B2 (en) |
| KR (1) | KR102534185B1 (en) |
| CN (1) | CN111448189A (en) |
| AU (1) | AU2019214089B2 (en) |
| BR (1) | BR112020014459A2 (en) |
| CA (1) | CA3088927C (en) |
| MX (1) | MX2020008205A (en) |
| PH (1) | PH12020551184A1 (en) |
| SG (1) | SG11202006409TA (en) |
| TW (1) | TWI828649B (en) |
| WO (1) | WO2019149183A1 (en) |
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN109803651B (en) | 2016-06-27 | 2022-05-31 | 凯莫森特里克斯股份有限公司 | Immunomodulatory compounds |
| WO2018200571A1 (en) | 2017-04-25 | 2018-11-01 | Arbutus Biopharma Corporation | Substituted 2,3-dihydro-1h-indene analogs and methods using same |
| IL272258B (en) | 2017-07-28 | 2022-08-01 | Chemocentryx Inc | Immunomodulator compounds |
| KR20200056989A (en) | 2017-08-08 | 2020-05-25 | 케모센트릭스, 인크. | Macrocyclic immunomodulator |
| US10568874B2 (en) | 2018-02-22 | 2020-02-25 | Chemocentryx, Inc. | Indane-amines as PD-L1 antagonists |
| JP2021520342A (en) * | 2018-04-03 | 2021-08-19 | ベータ ファーマシューティカルズ カンパニー リミテッド | Immunomodulators, compositions and methods thereof |
| CA3139526A1 (en) | 2019-05-15 | 2020-11-19 | Chemocentryx, Inc. | Triaryl compounds for treatment of pd-l1 diseases |
| KR20220024701A (en) | 2019-06-20 | 2022-03-03 | 케모센트릭스, 인크. | Compounds for the treatment of PD-L1 disease |
| WO2021007386A1 (en) | 2019-07-10 | 2021-01-14 | Chemocentryx, Inc. | Indanes as pd-l1 inhibitors |
| US20220380342A1 (en) * | 2019-07-18 | 2022-12-01 | Abbisko Therapeutics Co., Ltd. | Biphenyl derivatives for blocking pd-1/pd-l1 interaction, preparation method therefor and use thereof |
| US11713307B2 (en) | 2019-10-16 | 2023-08-01 | Chemocentryx, Inc. | Heteroaryl-biphenyl amides for the treatment of PD-L1 diseases |
| CA3152714A1 (en) | 2019-10-16 | 2021-04-22 | Pingchen Fan | Heteroaryl-biphenyl amines for the treatment of pd-l1 diseases |
| WO2021147940A1 (en) * | 2020-01-21 | 2021-07-29 | 上海华汇拓医药科技有限公司 | Pd-1/pd-l1 inhibitor, preparation method therefor, and use thereof |
| CN113248492B (en) * | 2020-02-10 | 2022-11-08 | 上海海雁医药科技有限公司 | Heterocycle substituted nitrogen-containing six-membered heterocyclic derivative, preparation method and medical application thereof |
| CN113493469A (en) * | 2020-03-18 | 2021-10-12 | 成都倍特药业股份有限公司 | Compound capable of being used as immunomodulator, preparation method and application thereof |
| CN114075123B (en) * | 2020-08-11 | 2023-06-06 | 中国人民解放军军事科学院军事医学研究院 | Benzylamine derivative and preparation method and application thereof |
| EP4159720A1 (en) | 2021-09-30 | 2023-04-05 | Recepton Spolka z Ograniczona Odpowiedzialnoscia | Nonsymmetric substituted 1,1'-biphenyl derivatives and uses thereof |
| WO2023169373A1 (en) * | 2022-03-07 | 2023-09-14 | 上海和誉生物医药科技有限公司 | Holosymmetric biphenyl derivative, and preparation method therefor and use thereof |
| CN117343006A (en) * | 2023-10-08 | 2024-01-05 | 河南科技大学 | Preparation method of ARB-272572 |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX2016002544A (en) | 2013-09-04 | 2016-06-17 | Squibb Bristol Myers Co | Compounds useful as immunomodulators. |
| MA44075A (en) | 2015-12-17 | 2021-05-19 | Incyte Corp | N-PHENYL-PYRIDINE-2-CARBOXAMIDE DERIVATIVES AND THEIR USE AS MODULATORS OF PROTEIN / PROTEIN PD-1 / PD-L1 INTERACTIONS |
| MX2018016273A (en) * | 2016-06-20 | 2019-07-04 | Incyte Corp | Heterocyclic compounds as immunomodulators. |
| CA3029857C (en) * | 2016-07-05 | 2023-07-04 | Guangzhou Maxinovel Pharmaceuticals Co., Ltd | Aromatic acetylene or aromatic ethylene compound, intermediate, preparation method, pharmaceutical composition and use thereof |
| AU2017305399A1 (en) * | 2016-08-03 | 2019-01-31 | Arising International, Inc. | Symmetric or semi-symmetric compounds useful as immunomodulators |
| MA46045A (en) * | 2016-08-29 | 2021-04-28 | Incyte Corp | HETEROCYCLIC COMPOUNDS USED AS IMMUNOMODULATORS |
| MD3558990T2 (en) * | 2016-12-22 | 2023-02-28 | Incyte Corp | Tetrahydro imidazo[4,5-c]pyridine derivatives as PD-L1 internalization inducers |
| ES2899402T3 (en) * | 2016-12-22 | 2022-03-11 | Incyte Corp | Pyridine derivatives as immunomodulators |
| JP2021520342A (en) | 2018-04-03 | 2021-08-19 | ベータ ファーマシューティカルズ カンパニー リミテッド | Immunomodulators, compositions and methods thereof |
-
2019
- 2019-01-29 EP EP19748336.5A patent/EP3750887A4/en active Pending
- 2019-01-29 CA CA3088927A patent/CA3088927C/en active Active
- 2019-01-29 BR BR112020014459-2A patent/BR112020014459A2/en active Search and Examination
- 2019-01-29 JP JP2020542156A patent/JP7033343B2/en active Active
- 2019-01-29 WO PCT/CN2019/073594 patent/WO2019149183A1/en unknown
- 2019-01-29 KR KR1020207020538A patent/KR102534185B1/en active IP Right Grant
- 2019-01-29 CN CN201980005084.9A patent/CN111448189A/en active Pending
- 2019-01-29 SG SG11202006409TA patent/SG11202006409TA/en unknown
- 2019-01-29 AU AU2019214089A patent/AU2019214089B2/en active Active
- 2019-01-29 MX MX2020008205A patent/MX2020008205A/en unknown
- 2019-01-29 US US16/967,030 patent/US11459339B2/en active Active
- 2019-01-30 TW TW108103459A patent/TWI828649B/en active
-
2020
- 2020-08-05 PH PH12020551184A patent/PH12020551184A1/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| EP3750887A4 (en) | 2021-10-20 |
| RU2768830C2 (en) | 2022-03-24 |
| JP7033343B2 (en) | 2022-03-10 |
| TWI828649B (en) | 2024-01-11 |
| KR102534185B1 (en) | 2023-05-18 |
| CN111448189A (en) | 2020-07-24 |
| JP2021512878A (en) | 2021-05-20 |
| RU2020127950A3 (en) | 2022-03-11 |
| CA3088927A1 (en) | 2019-08-08 |
| AU2019214089B2 (en) | 2021-02-11 |
| PH12020551184A1 (en) | 2021-05-10 |
| US20210032270A1 (en) | 2021-02-04 |
| TW201934544A (en) | 2019-09-01 |
| CA3088927C (en) | 2023-03-21 |
| MX2020008205A (en) | 2020-09-18 |
| EP3750887A1 (en) | 2020-12-16 |
| AU2019214089A1 (en) | 2020-07-09 |
| KR20200100717A (en) | 2020-08-26 |
| BR112020014459A2 (en) | 2020-12-15 |
| RU2020127950A (en) | 2022-03-11 |
| WO2019149183A1 (en) | 2019-08-08 |
| US11459339B2 (en) | 2022-10-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SG11202006409TA (en) | Biaryl derivative, preparation method therefor and pharmaceutical use thereof | |
| HK1255566A1 (en) | Oxopicolinamide derivative, preparation method therefor and pharmaceutical use thereof | |
| HUE054964T2 (en) | Pyrazolo-heteroaryl derivative, preparation method and medical use thereof | |
| EP3524603A4 (en) | Fgfr4 inhibitor, preparation method therefor and pharmaceutical use thereof | |
| HK1251551A1 (en) | Azetidine derivative, preparation method therefor, and use thereof | |
| SG11202003782XA (en) | Triple-chain antibody, method for preparation and use thereof | |
| ZA201804362B (en) | Mutant virus, preparation method therefor and application thereof | |
| EP3378859A4 (en) | Benzofuran derivative, preparation method thereof and use thereof in medicine | |
| EP3632907C0 (en) | N-(azaaryl)cyclolactam-1-carboxamide derivative, preparation method therefor, and use thereof | |
| EP3730491A4 (en) | Isoxazole derivative, preparation method therefor, and use thereof | |
| EP3636646A4 (en) | Heteroaryl-pyrazole derivative, and preparation method therefor and medical application thereof | |
| EP3351242A4 (en) | Cannabinoid-containing oral pharmaceutical composition, method for preparing and using same | |
| IL272446A (en) | Substituted penta- fused hexa-heterocyclic compounds, preparation method therefor, drug combination and use thereof | |
| EP3251698A4 (en) | Ligand-cytotoxicity drug conjugate, preparing method therefor, and application thereof | |
| EP3369734A4 (en) | Kinase inhibitor, and preparing method and pharmaceutical use thereof | |
| EP3231802A4 (en) | Pyridinecarboxamide derivatives, preparation method therefor and pharmaceutical uses thereof | |
| EP3589670A4 (en) | Elastomer, method for preparation thereof, and use thereof | |
| IL276244A (en) | Ophthalmic pharmaceutical composition, preparation method therefor and application thereof | |
| ZA201908091B (en) | Indole-formamide derivative, preparation method therefor and use thereof in medicine | |
| EP3653202A4 (en) | Pharmaceutical preparation and preparation method therefor | |
| EP3395366A4 (en) | Drug design method, obtained drug and application thereof | |
| EP3388433A4 (en) | Phthalazine derivatives, and preparation method, pharmaceutical composition and use thereof | |
| EP3632906C0 (en) | Azaaryl derivative, preparation method therefor, and application thereof for use in pharmacy | |
| EP3581561A4 (en) | Biaryl compound, preparation method and use therefor | |
| EP3569613A4 (en) | Erythropoietin-derived peptide, preparation method therefor, and use thereof |